Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.

Twenty-four assessable patients with hormone-resistant prostate cancer (HRPC) were to receive daily doses of oral estramustine phosphate (EMP), 10 mg kg(-1), and intravenous epirubicin (EPR) infusions, 100 mg m(-2), every third week up to a cumulative dose of 500 mg m(-2). Biochemical response [>...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hernes, E. H., Fosså, S. D., Vaage, S., Ogreid, P., Heilo, A., Paus, E.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 1997
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2223802/
https://ncbi.nlm.nih.gov/pubmed/9218739
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki